Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q2 EPS by 13c, Revenues Miss
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $83.99 +4.41%
Revenue Growth %: +89.8%
Financial Fact:
OPERATING LOSS: -19.34M
Today's EPS Names:
CRMT, More
Revenue Growth %: +89.8%
Financial Fact:
OPERATING LOSS: -19.34M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of ($0.26), $0.13 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $32.81 million versus the consensus estimate of $37.7 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- FactSet Research Systems (FDS) PT Raised to $253 at Jefferies
- Waste stocks ride AI and healthcare boom as CLH surges 27%
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
